Mobile version of Hanspub

文章引用说明 更多>> (返回到该文章)

Johnson, D.H., Fehrenbiicher, L., Novotny, W.F., et al. (2004) Randomized Phase II Trial Comparing Bevacizumab plus Car-boplatin and Paclitaxel with Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer. Journal of Clinical Oncology, 22, 2184-2191.
http://dx.doi.org/10.1200/JCO.2004.11.022

被以下文章引用:

  • 标题: 非小细胞肺癌分子靶向治疗研究进展Research Progress of Molecular Target Therapy in Non-Small Cell Lung Cancer

    作者: 张琨, 寿伟臻

    关键字: 非小细胞肺癌, 靶向治疗, 研究进展Non-Small Cell Lung Cancer, Targeted Therapy, Research Progress

    期刊名称: 《Advances in Clinical Medicine》, Vol.6 No.1, 2016-03-03

    摘要: 肺癌是一种发病率、病死率均较高的恶性肿瘤,临床上多采用手术、放疗、化疗等治疗手段,但是不得不承认的是,除了对于早期肺癌及体质较好的患者有较为可观的疗效外,其治疗效果的上升空间相对局限。肺癌分子靶向治疗与传统的手术、放疗、化疗相比,因其与肿瘤细胞上特有的靶点产生特异性结合,精确打击肿瘤细胞而又不伤害正常的细胞,从而具有毒副反应较小的优点,这种新的治疗方式提高了患者的生活质量。本文对肺癌生物靶向治疗药物的研究进展进行综述。 Lung cancer is a malignant tumor with high incidence rate and mortality rate. Clinically, treatment means, like surgery, radiotherapy, chemotherapy treatment, etc. are used. However, it had to admit that, besides the considerable effect for patients with early lung cancer and patients with good physique, the rising space of the treatment effect relatively limited. Lung cancer molecular target-ing therapy, compared with traditional surgery, radiotherapy and chemotherapy, due to its specific binding to the specific target of tumor cells, precisely attacking tumor cells without harm to the normal cells, has got the advantage of less toxic side effect. This new treatment modality improves patients’ life quality. This paper reviewed the research progress of drug treatment to lung cancer biological target.